Cargando…

Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease

BACKGROUND: Tolvaptan slowed the rates of total kidney volume (TKV) growth and renal function decline over a 3-year period in patients with autosomal dominant polycystic kidney disease (ADPKD) enrolled in the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horie, Shigeo, Muto, Satoru, Kawano, Haruna, Okada, Tadashi, Shibasaki, Yoshiyuki, Nakajima, Koji, Ibuki, Tatsuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038960/ https://www.ncbi.nlm.nih.gov/pubmed/33471240 http://dx.doi.org/10.1007/s10157-020-02009-0

Ejemplares similares

Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan
por: Muto, Satoru, et al.
Publicado: (2021)

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial
por: Muto, Satoru, et al.
Publicado: (2017)

PKD1 Mutation Is a Biomarker for Autosomal Dominant Polycystic Kidney Disease
por: Kimura, Tomoki, et al.
Publicado: (2023)

Renal disease progression in autosomal dominant polycystic kidney disease
por: Higashihara, Eiji, et al.
Publicado: (2012)

Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
por: Gilbert, Rodney D., et al.
Publicado: (2017)

Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
por: Bellos, Ioannis
Publicado: (2021)

Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease
por: Magistroni, Riccardo
Publicado: (2018)

Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
por: Kim, Ha Yeon, et al.
Publicado: (2018)

Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
por: Anderegg, Manuel A., et al.
Publicado: (2020)

Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance
por: Mochizuki, Toshio, et al.
Publicado: (2021)

Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Sekine, Akinari, et al.
Publicado: (2022)

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
por: Sans-Atxer, Laia, et al.
Publicado: (2018)

Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
por: Müller, Roman-Ulrich, et al.
Publicado: (2018)

Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
por: Kunizawa, Kyohei, et al.
Publicado: (2018)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022)

Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
por: Iijima, Hiroko, et al.
Publicado: (2022)

Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2023)

Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
por: Kim, Yaerim, et al.
Publicado: (2023)

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
por: Grantham, Jared J., et al.
Publicado: (2017)

Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
por: Lanke, Shankar, et al.
Publicado: (2019)

Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients
por: Nakatani, Shinya, et al.
Publicado: (2020)

Tolvaptan ameliorated kidney function for one elderly autosomal dominant polycystic kidney disease patient: A case report
por: Zhou, Li, et al.
Publicado: (2022)

Autosomal dominant polycystic kidney
por: Gudadhe, Rugaved Raghavendra, et al.
Publicado: (2022)

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial
por: Casteleijn, Niek F., et al.
Publicado: (2016)

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022)

Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022)

Safety and Tolerability of Tolvaptan in an Autosomal Dominant Polycystic Kidney Disease Spanish Cohort: A Real-World Experience
por: Guerra-Torres, Xavier E, et al.
Publicado: (2020)

Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations
por: Moriyama, Tomofumi, et al.
Publicado: (2020)

Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease
por: Naranjo, Javier, et al.
Publicado: (2022)

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis
por: Lioudis, Michael, et al.
Publicado: (2023)

Feasibility of artificial intelligence-based decision supporting system in tolvaptan prescription for autosomal dominant polycystic kidney disease
por: Shin, Jung Hyun, et al.
Publicado: (2023)

Kidney volume and function in autosomal dominant polycystic kidney disease
por: Higashihara, Eiji, et al.
Publicado: (2013)

Autosomal dominant polycystic kidney disease in Colombia
por: Camargo, Jessica T., et al.
Publicado: (2023)

Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)
por: Agraz-Pamplona, I., et al.
Publicado: (2020)

The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial
por: Uchiyama, Kiyotaka, et al.
Publicado: (2021)

Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis
por: Lu, Jingkui, et al.
Publicado: (2022)

Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies
por: Chebib, Fouad T., et al.
Publicado: (2023)

An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
por: Müller, Roman-Ulrich, et al.
Publicado: (2021)

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
por: Watkins, Paul B., et al.
Publicado: (2015)

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum]
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bls7673qjucaqe588tl8k2nfdr